Google DeepMind Launches AlphaGenome AI Processing 1 Million DNA Base Pairs, Targeting Non-Coding DNA and Cancer Research, Available via API

38 posts • GPT (4.1 mini)

Published Jul 6, 2025, 09:35 PM

Google DeepMind has launched AlphaGenome, an advanced artificial intelligence model designed to analyze and predict the impact of single nucleotide variants or mutations across extensive human DNA sequences. AlphaGenome processes up to one million DNA base pairs at once, enabling comprehensive predictions of how genetic changes affect molecular functions such as gene regulation, RNA splicing, and protein production. The model notably addresses both protein-coding and non-coding regions of the genome, including the previously less understood "dark matter" or non-protein-coding DNA, which constitutes approximately 98% of human DNA. Available via an API for non-commercial research, AlphaGenome aims to accelerate biological discoveries, advance synthetic biology, and enhance the search for cancer-related genes. It builds on DeepMind's earlier success with AlphaFold, which predicted protein structures, and represents a leap forward in precision medicine by potentially enabling real-time disease risk prediction and more efficient drug development. DeepMind's broader ambitions include leveraging AI to cure diseases, with plans underway for first human trials of AI-designed drugs later in 2025 through its affiliated company, Isomorphic Labs.

More breaking stories on DeepNewz — updated live.

#Google DeepMind #AlphaGenome #DeepMind #AlphaFold #Isomorphic Labs

Financial Analysis

Associated Financial Markets

More financial news and market updates→

Related Prediction Markets

Which company has best AI model end of 2025?

Which company has best AI model on June 30?

Which company has best AI model end of August?

•

Sources

science.org(4)decrypt.co(3)lifeboat.com(2)nature.com(2)

Dylan Curious | AI News & Analysis

@dylan_curious

DeepMind Pushes ‘Cure-All’ Drugs Into First Human Trials Fortune reports Isomorphic Labs will test AI-designed molecules in patients later this year, aiming to rewrite pharma. If lab-to-patient cycles shrink tenfold, who redefines drug safety? For more AI News, follow

Chubby♨️

@kimmonismus

So it begins, The cure for all diseases "Google DeepMind has grand ambitions to cure all diseases with AI. Now it's gearing up for its first human trials" Via Bloomberg. We are entering the trial phase. What a time to be alive.

Haider.

@slow_developer

Fortune reported: "Google DeepMind has grand ambitions to cure all diseases with AI. Now it's gearing up for its first human trials" this is the moment. generative design of drugs is my go-to example to show AI isn't just hype. this is why AGI or ASI matter — to solve